Scholarlink

Background <p>Urothelial bladder cancer (UBC) is the ninth most common cancer worldwide. It is essential to investigate factors that may affect susceptibility and determine the prognosis of UBC. IRF5 is an interferon regulatory factor that modulates cellular differentiation during immune responses and oncogenesis.</p> Methods and results <p>The frequency of the rs3757385 (T &gt; G) variant in <i>IRF5</i> was evaluated in 295 patients with UBC and 295 individuals without neoplasia in a Brazilian population. Nitric oxide metabolites (NOx) systemic levels and <i>IRF5</i> expression in normal and tumoral bladder tissues were also evaluated, as was the interaction between these parameters and prognostic indicators. Bioinformatics analyses compared gene expression patterns with TCGA data. The polymorphism was not associated with susceptibility to UBC. The mutated allele (G) was associated with a decrease in the relapses in the genotypic (OR = 0.205) and dominant (OR = 0.380) models. Hypertensive individuals with TG (genotypic, OR = 0.079) or TG + GG (dominant model, OR = 0.184) had fewer muscle-invasive tumors. Polymorphism did not alter the plasmatic NOx levels. Higher <i>IRF5</i> expression was observed in patients with at least one G allele, males, smokers, and alcoholics. Directly, NOx was not associated with the prognostic parameters; however, individuals with the G allele and high NOx levels showed protection against relapses.</p> Conclusion <p>Our study highlights the association between rs3757385 (G allele) and high plasmatic NOx levels as good prognostic factors in UBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide metabolites, protecting urothelial bladder cancer patients from recurrence

  • 期刊论文

  • 发表日期：

    2025年6月28日

查看全文
  • Ariane P. Souza,
  • Isabely M. Silva,
  • Beatriz G. L. Vacario,
  • Alexsandro Koike,
  • Rafael G. Paz,
  • Carolina Coradi,
  • Emily M. S. Wrzesinski,
  • Guilherme L. Trigo,
  • Andrea N. C. Simão,
  • Marcell A. B. Lozovoy,
  • Roberta L. Guembarovski,
  • Carolina Panis,
  • Juliana Mara Serpeloni

摘要

Background

Urothelial bladder cancer (UBC) is the ninth most common cancer worldwide. It is essential to investigate factors that may affect susceptibility and determine the prognosis of UBC. IRF5 is an interferon regulatory factor that modulates cellular differentiation during immune responses and oncogenesis.

Methods and results

The frequency of the rs3757385 (T > G) variant in IRF5 was evaluated in 295 patients with UBC and 295 individuals without neoplasia in a Brazilian population. Nitric oxide metabolites (NOx) systemic levels and IRF5 expression in normal and tumoral bladder tissues were also evaluated, as was the interaction between these parameters and prognostic indicators. Bioinformatics analyses compared gene expression patterns with TCGA data. The polymorphism was not associated with susceptibility to UBC. The mutated allele (G) was associated with a decrease in the relapses in the genotypic (OR = 0.205) and dominant (OR = 0.380) models. Hypertensive individuals with TG (genotypic, OR = 0.079) or TG + GG (dominant model, OR = 0.184) had fewer muscle-invasive tumors. Polymorphism did not alter the plasmatic NOx levels. Higher IRF5 expression was observed in patients with at least one G allele, males, smokers, and alcoholics. Directly, NOx was not associated with the prognostic parameters; however, individuals with the G allele and high NOx levels showed protection against relapses.

Conclusion

Our study highlights the association between rs3757385 (G allele) and high plasmatic NOx levels as good prognostic factors in UBC.